Thermo Fisher Scientific Inc.
HealthcareNYSE:TMO · New York Stock Exchange
-$6.09 today
Vol 0.58M · Avg 2.36M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.6%
avg 12.9%
ROIC
7.6%
avg 8.0%
ROA
6.1%
avg 6.2%
Analysis
ROE is currently the strongest return metric at 12.6% versus its period average of 12.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Marc N. Casper | Chairman & CEO | $6.24M | — | 58 | $127,905.36 | 0.03% |
James Meyer | Senior Vice President & Chief Financial Officer | $3.01M | — | 46 | $0.00 | <0.01% |
Gianluca Pettiti | President, COO & President of Products and Technologies | $2.42M | — | 47 | $25,050.83 | <0.01% |
Alan J. Malus | Senior Vice President of Strategy & Corporate Development | $1.77M | — | 66 | — | — |
Thomas Bailey Shropshire Jr. | Senior Vice President and General Counsel | $1.76M | — | — | $6,057.52 | <0.01% |
Karen E. Nelson | Chief Scientific Officer | — | — | — | $15,316.00 | <0.01% |
Joseph R. Holmes | Vice President & Chief Accounting Officer | — | — | 46 | $2,602.00 | <0.01% |
Rafael Tejada | Vice President of Investor Relations | — | — | — | — | — |
Ryan J. Snyder | Senior Vice President & Chief Information Officer | — | — | — | — | — |
Sandy Pound | Vice President & Chief Communications Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
70
$91.46M
Net Sentiment
$91.46M
Net selling
Most Active
CASPER MARC N
52 transactions
1–10 of 70
Analysis
Insiders reported 0 buys worth $0.00 and 70 sells worth $91.46M over the last 12 months. That adds up to net selling of $91.46M. CASPER MARC N was the most active insider with 52 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +15.3% | +14.6% (15yr)1 analysts |
| Revenue | N/A | N/A | +10.7% | +8.6% (15yr)7 analysts |
| Net Income | N/A | N/A | +18.8% | +14.1% (15yr)7 analysts |
| EBIT | N/A | N/A | +15.3% | +10.9% (15yr)7 analysts |
Analysis
Recent growth has been strongest in Net Income at +18.8% over three years. Forward estimates point to EPS at +14.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$296.00B
Novartis AG
NYSE:NVS
$292.70B
AstraZeneca PLC
NYSE:AZN
$278.81B
Novo Nordisk A/S
NYSE:NVO
$196.64B
Amgen Inc.
NASDAQ:AMGN
$190.71B
Abbott Laboratories
NYSE:ABT
$152.86B
Intuitive Surgical, Inc.
NASDAQ:ISRG
$144.58B
Danaher Corporation
NYSE:DHR
$127.55B
Agilent Technologies, Inc.
NYSE:A
$36.44B
IQVIA Holdings Inc.
NYSE:IQV
$29.86B
Who manages TMO?
Thermo Fisher Scientific Inc. (TMO) lists 10 active executives. The top listed executive is Gianluca Pettiti, President, COO & President of Products and Technologies.
Are TMO insiders buying or selling?
Recent insider activity shows net selling of $62.51M.
Explore More
Continue the stock analysis
Jump to another research area for this company.